全文获取类型
收费全文 | 155篇 |
免费 | 2篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 1篇 |
临床医学 | 5篇 |
内科学 | 12篇 |
神经病学 | 1篇 |
特种医学 | 71篇 |
外科学 | 18篇 |
预防医学 | 1篇 |
药学 | 5篇 |
肿瘤学 | 42篇 |
出版年
2021年 | 2篇 |
2019年 | 2篇 |
2018年 | 2篇 |
2016年 | 2篇 |
2015年 | 2篇 |
2014年 | 2篇 |
2013年 | 6篇 |
2012年 | 7篇 |
2011年 | 3篇 |
2010年 | 4篇 |
2009年 | 5篇 |
2008年 | 5篇 |
2007年 | 4篇 |
2006年 | 4篇 |
2005年 | 7篇 |
2004年 | 3篇 |
2003年 | 8篇 |
2002年 | 7篇 |
2001年 | 10篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1992年 | 9篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 8篇 |
1983年 | 2篇 |
1981年 | 1篇 |
排序方式: 共有157条查询结果,搜索用时 93 毫秒
1.
B L Bower D Picus M E Hicks M D Darcy E S Rollins M A Kleinhoffer P J Weyman 《Journal of vascular and interventional radiology : JVIR》1990,1(1):107-112
Retained biliary stones remain a common clinical problem in patients after surgery. Since 1984, the authors have used choledochoscopy in the treatment of suspected retained biliary stones in 75 patients. These procedures were performed in the radiology department with use of local anesthesia supplemented by an intravenously administered sedative and analgesic. A 15-F flexible fiberoptic choledochoscope was used. Fifty-one of the 75 patients were treated as outpatients. Treatment was successful in 74 of 75 patients; in one patient, intrahepatic stones were not completely removed. Electrohydraulic lithotripsy was used to fragment calculi in 11 patients (15%). Biopsies were performed in four patients (5%). Five minor complications occurred; three required overnight admission. Choledochoscopic-assisted removal of retained biliary calculi is a highly effective and safe procedure. Advantages over standard fluoroscopic stone removal include the ability to directly visualize and fragment adherent or impacted stones and visualize noncalculous filling defects, such as air bubbles, mucus, and biliary tumors. 相似文献
2.
3.
4.
5.
6.
John W Picus J Blanke CD Clark JW Schulman LN Rowinsky EK Thornton DE Loehrer PJ 《Cancer》2000,88(8):1807-1813
BACKGROUND: The aim of this study was to confirm the activity and assess the safety profile of multitargeted antifolate (MTA) for patients with metastatic colorectal adenocarcinoma. METHODS: Forty-six patients were enrolled in the study, 35 with colon and 11 with rectal carcinoma. Adjuvant therapy was allowed if completed 1 year previously. Patients received MTA 600 mg/m(2) as a 10-minute intravenous infusion once every 21 days. Blood samples were taken every cycle for pharmacokinetic and vitamin metabolite assays. RESULTS: Among 39 patients eligible for efficacy analysis, 1 complete response and 5 partial responses were identified, for an overall response rate of 15.4% (95% confidence interval [CI], 4.1-26. 7%) for all patients. Fifteen patients had stable disease, with 9 living longer than 1 year. The median survival was 16.2 months (95% CI, 10.5-17.0%); 65% of patients were alive at 1 year, and the median time to progression was 4.4 months (range, 3.2-5.7 months). The main toxicities were hematologic, with common toxicity criteria (CTC) Grades 3 or 4 noted as follows: thrombocytopenia (18%), neutropenia (55%), and anemia (18%). Nonhematologic toxicities included Grade 2 or 3 skin reaction (53%), ameliorated by dexamethasone, and Grade 3 transaminases (23%). Dose omissions were not required and 21% of doses were reduced. CONCLUSIONS: MTA has clear activity in patients with colorectal carcinoma, and encouraging survival times were noted. MTA was well tolerated in this patient group, but myelosuppression was frequent. Toxicity may be increased with folate deficiency. 相似文献
7.
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma 总被引:14,自引:0,他引:14
Kibel AS Suarez BK Belani J Oh J Webster R Brophy-Ebbers M Guo C Catalona WJ Picus J Goodfellow PJ 《Cancer research》2003,63(9):2033-2036
A multigenic model of prostate cancer susceptibility has been proposed, in which common polymorphic variants of genes, such as the androgen and vitamin D receptor, contribute to tumorigenesis. The discovery of additional genetic factors that contribute to prostate cancer risk should provide opportunities for new approaches to the detection and treatment of this common malignancy. Herein, we examined single nucleotide polymorphic variants in the 3'-untranslated region of CDKN1A (p21(cip1)) and in codon 109 of CDKN1B (p27(kip1)) for association with advanced prostate cancer in a European-American population. Ninety-six cases and 106 controls were analyzed using PCR amplification and restriction digestion assays. CDKN1A genotype was scored as CC, CT, and TT on the basis of the digestion products. The CDKN1A genotypes CT and TT were associated with an increased risk of advanced prostate carcinoma compared with the CC genotype [odds ratio (OR), 2.24; 95% confidence interval (CI), 1.02-4.95]. The CDKN1B genotype was scored as VV, VG, or GG, again on the basis of the digestion products. The CDKN1B genotype VV was also associated with an increased risk of advanced prostate carcinoma (OR, 1.95; 95% CI, 1.09-3.47). These associations were particularly strong in those patients with androgen-independent disease [OR = 2.88 (95% CI, 1.19-6.97) and 2.11 (95% CI, 1.05-4.22) for high-risk genotypes of CDKN1A and CDKN1B, respectively]. In addition, the association of CDKN1B was particularly strong in the cohort of patients under the median age of diagnosis (OR, 2.23; 95% CI, 1.08-4.59). These results suggest that in a European-American population, CDKN1A and CDKN1B variants are associated with advanced prostate cancer. Analysis of CDKN1A and/or CDKN1B genotypes may prove useful in determining which patients are at risk for developing advanced prostate carcinoma and therefore would gain the most from aggressive screening, prophylaxis, and/or treatment. 相似文献
8.
9.
10.